Video

Dr Lawrence Shulman Discusses the Role of Rising Drug Costs in Value-Based Care

Lawrence N. Shulman, MD, director of the Center for Global Cancer Medicine at the Abramson Cancer Center, and professor of Medicine at the Hospital of the University of Pennsylvania, explains how providers are reacting to more effective, more costly therapies entering the cancer landscape.

Lawrence N. Shulman, MD, director of the Center for Global Cancer Medicine at the Abramson Cancer Center, and professor of Medicine at the Hospital of the University of Pennsylvania, explains how providers are reacting to more effective, more costly therapies entering the cancer landscape.

Transcript

As drug costs continue to rise, is value-based care changing the way providers make treatment decisions for patients with cancer?

I think the good news is, over the last couple of years, we’ve had a lot of new cancer therapies, which have radically changed the prognosis for our patients in diseases like melanoma and lung cancer. But, I think we all know those new treatments have come with a huge cost. They are so much better in so many cases than our old treatments. I don’t think oncologists or other specialists, in fact, make decisions based on cost. They make decisions based on what the best therapies are that are available for their patients, and particularly when there’s a big difference between the new therapy and the old therapy.

Related Videos
Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center
Jawad Haider Butt, MD, PhD
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Adam Colburn, JD, vice president for congressional affairs, AMCP
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo